Summary
This paper gives an update on the mechanisms of bacterial resistance to fluoroquinolones. The laboratory techniques currently used to determine the mechanism(s) of resistance are outlined, including the use of restriction fragment length polymorphism and single-stranded conformational polymorphism analysis of mutations in gyrA. Alterations in gyrA have continued to be the most reported cause of resistance, with high level resistance due to 2 or more mutations in this gene. Recently, mutations in gyrA of Mycobacterium tuberculosis and Campylobacter jejuni have been described. Complementation studies with plasmid encoded cloned gyrB from Escherichia coli suggest that high fluoroquinolone resistance (minimum inhibitory concentration = 32 mg/L) in Salmonella typhimurium can be due to mutation in both gyrA and gyrB.
Decreased fluoroquinolone accumulation into E. coli has been shown to be due to mutations in a number of genes at different loci. Current interest has focused upon the marRAB and soxRS loci, with mutations in genes of either loci giving rise to decreased susceptibility to several unrelated drugs, including fluoroquinolones, tetracycline, chloramphenicol and some β-lactams, and decreased expression of OmpF. The genetic characterisation of fluoroquinolone efflux from Staphylococcus aureus has shown that efflux occurs in both fluoroquinolone-susceptible and -resistant bacteria. The most likely cause of resistance is overexpression of NorA, giving rise to increased efflux. Recently, 2 efflux systems in Pseudomonas aeruginosa have been proposed, MexA-MexB-OprK and MexC-MexD-OprM, conferring decreased susceptibility to fluoroquinolones, tetracycline, chloramphenicol and some β-lactams.
To date, most clinical fluoroquinolone resistance has been due to mutations in gyr A; however, with the continued increase in the use of these agents bacteria will continue to employ different tactics to evade their action. It is likely that high level fluoroquinolone resistance will emerge in previously susceptible species because of several mutations in one or several genes.
Similar content being viewed by others
References
Piddock LJV. Resistance to quinolones and fluoroquinolones. In: Bryan LE, editor. Handbook of experimental pharmacology: microbial resistance to drugs. Heidelberg: Springer-Verlag, Chapter 8, 1989: 169-92
Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl. 3: 15–23
Robillard N. Broad host range gyrase A gene probe. Antimicrob Agents Chemother 1990; 34: 1889–94
Heisig P, Wiedemann B. Use of a broad-host-range gyrA plasmid for genetic characterisation of fluoroquinolone-resistant Gram-negative bacteria. Antimicrob Agents Chemother 1991; 35: 2031–6
Heisig P, Tschorny R. Characterisation of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284–91
Tokue Y, Sugano K, Saito D, et al. Detection of novel mutations in gyrA gene of Staphylococcus aureus by nonadioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. Antimicrob Agents Chemother 1994; 38: 310–428
Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of M. tuberculosis gyrA and gytrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773–80
Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterisation of quinolone resistance mutations. Antimicrob Agents Chemother 1993; 37: 457–63
Cullen ME, Wyke AW, Kuroda R, et al. Cloning and characterisation of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother 1989; 33: 886–94
Yamagishi J, Yoshida H, Yamayichi M, et al. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367–73
Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1994; 32: 367–77
Piddock LJV. Mechanism of quinolone uptake into bacterial cells. J Antimicrob Chemother 1991; 27: 399–405
Hirai K, Aoyama H, Suzue S, et al. Isolation and characterisation of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 1986; 30: 248–53
Hooper D, Wolfson J, Souza KS, et al. Genetic and biochemical characterisation of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1986; 29: 638–44
Greenberg JT, Chou JH, Monach PA, et al. Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli. J Bacteriol 1991; 173: 433–9
Hooper DC, Wolfson JS, Souza KS, et al. Mechanisms of quinolone resistance in Escherichia coli: characterisation of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother 1989; 33: 283–90
Hrebenda J, Heleszko H, Brostek K, et al. Mutation affecting resistance of Escherichia coli K12 to nalidixic acid. J Gen Microbiol 1985; 131: 2285–92
Miller PF, Gambino LF, Sulvik MC, et al. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 1994; 38: 1773–9
Ariza RR, Cohen SP, Bachhawat N, et al. Repressor mutations in the maRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli. J Bacteriol 1994; 176: 143–48
Cohen SP, Hooper DC, Wolfson JS, et al. Endogenous active efflux of norfloxacin in susceptible E. coli. Antimicrob Agents Chemother 1988; 32: 1187–91
Yoshida H, Bogaki M, Nakamura S, et al. Nucleotide sequence and characterisation of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172: 6942–9
Yoshida H, Kojima T, Inoue M, et al. Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 368–70
Oshita Y, Hiramatsu K, Yokota T. A point mutation in the norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun 1990; 172: 1028–34
Kaatz GW, Seo SM, Ruble CA. Efflux mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 1086–94
Poole K, Krebes K, McNally K, et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 7363–72
Li X-Z, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob Agents Chemother 1994; 38: 1732–41
Nakashini N, Yoshida S, Wakebe H, et al. Mechanisms and clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 2562–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Piddock, L.J.V. Mechanisms of Resistance to Fluoroquinolones: State-of-the-Art 1992–1994. Drugs 49 (Suppl 2), 29–35 (1995). https://doi.org/10.2165/00003495-199500492-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199500492-00006